National Institute of Diabetes and Digestive and Kidney Diseases
Overview
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is an institute within the U.S. National Institutes of Health (NIH). Its mission is to conduct and support medical research and research training, and to disseminate science-based information on a wide range of serious, chronic diseases. The institute provides funding for research through grants to universities and other medical research institutions, including through Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. It also supports government scientists conducting basic, translational, and clinical research.
Portfolio Companies
23
Website
niddk.nih.govInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Genalyte | Dec 2012 | Grant | Co-investor |
| akston biosciences corporation | Jun 2019 | Grant | Co-investor |
| Syntis Bio, Inc. | Jul 2025 | Grant | Co-investor |
| HepaTx Corporation | May 2025 | Grant | Lead |
| Promakhos Therapeutics | Sep 2023 | Grant | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is National Institute of Diabetes and Digestive and Kidney Diseases based?
National Institute of Diabetes and Digestive and Kidney Diseases is headquartered in Bethesda, Maryland, United States.
When was National Institute of Diabetes and Digestive and Kidney Diseases founded?
Founding year information for National Institute of Diabetes and Digestive and Kidney Diseases is not publicly available.
How many portfolio companies does National Institute of Diabetes and Digestive and Kidney Diseases have?
National Institute of Diabetes and Digestive and Kidney Diseases has 23 portfolio companies in Caplight's dataset.
What are some companies in National Institute of Diabetes and Digestive and Kidney Diseases's portfolio?
Portfolio companies visible on Caplight include Genalyte, akston biosciences corporation, Syntis Bio, Inc., HepaTx Corporation, Promakhos Therapeutics.
What was National Institute of Diabetes and Digestive and Kidney Diseases's most recent investment shown here?
National Institute of Diabetes and Digestive and Kidney Diseases's most recent investment in this portfolio sample was in Syntis Bio, Inc. in 2025.
What sectors does National Institute of Diabetes and Digestive and Kidney Diseases focus on?
National Institute of Diabetes and Digestive and Kidney Diseases focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech.
What company stages does National Institute of Diabetes and Digestive and Kidney Diseases focus on?
National Institute of Diabetes and Digestive and Kidney Diseases typically invests at the MultiStage stage.